Tango Therapeutics, Inc.

TNGX

NASDAQHealthcareBiotechnology

在 GoAI 中打开

GoAI 研究快照

简明呈现最新可用的模型信息。

2026年7月10日

57/ 100

GoAI评分

Hold

Wait — insufficient conviction to act

估值

Fair Value

动量

Gaining

情绪

Bullish

风险韧性

Elevated Risk

完整 GoAI 研究

继续查看更深入的依据、催化因素和风险。

查看完整研究

人工智能生成的上下文仅供参考，并非投资建议。

公司概况

公司网站

Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions. Additionally, their pipeline includes an Ubiquitin-specific protease 1 (USP1) inhibitor targeting BRCA1 or BRCA2-mutant cancers, and a program known as 'Target 3' which addresses STK11-mutant cancers. Tango Therapeutics maintains a strategic alliance with Gilead Sciences, Inc., focused on the identification, advancement, and commercialization of a diverse array of cancer therapies. Established in 2017, the company's operations are headquartered in Cambridge, Massachusetts.

行业: Biotechnology
部门: Healthcare
总部: US
首席执行官: Malte Peters
上市以来: 2020年9月3日
雇员: 137